Etiologic Pathogenesis of Melanoma: A Unifying Hypothesis for the Missing Attributable Risk

Clinical Cancer Research

Volumn 10, Issue 8, 2004, Pages 2581-2583

  Meyskens Jr , Frank L ^a   Farmer, Patrick J ^a   Anton Culver, Hoda ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; REACTIVE OXYGEN METABOLITE;

CANCER CELL; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CELL DAMAGE; DISEASE COURSE; DNA DAMAGE; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEALTH SURVEY; HUMAN; HYPOTHESIS; MELANOCYTE; MELANOMA; MOLECULAR MECHANICS; OCCUPATIONAL HAZARD; OXIDATION; OXIDATION REDUCTION REACTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; ULTRAVIOLET RADIATION;

CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DNA DAMAGE; HUMANS; MELANINS; MELANOMA; MODELS, BIOLOGICAL; MUTATION; OXIDATION-REDUCTION; OXYGEN; RISK; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 1942534520     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0638     Document Type: Review

References (44)

1. Beddingfield FC III. The melanoma epidemic: res ipsa loquitur. Oncologist 2002;8:459-65.
2. Lamberg L. "Epidemic" of malignant melanoma: true increase or better detection. J Am Med Assoc 2002;287:2201.
3. Dennis LK. Analysis of the melanoma epidemic, both apparent and real: data from the 1973 through 1994 surveillance, epidemiology, and end results program registry. Arch Dermatol 1999;135:275-80.
4. Lipsker DM, Hedelin G, Heid E, Grosshans EM, Cribier BJ. Striking increases of thin melanomas contrasts with a stable incidence of thick melanomas. Arch Dermatol 1999;135:1451-6.
5. MacKie RM, Marks R, Green A. The melanoma epidemic. Excess exposure to ultraviolet light is established as major risk factor. Br Med J 1996;312:1362-3.
6. Wernstock M, Colditz G, Willett W, Stampfer M, Bronstein B, Mihm M, Speizer F. Nonfamilial cutaneous melanoma incidence in women associated with sun exposure before 20 years of age. Pediatrics 1989;84:199-204.
7. Green A, Williams G. UV and skin cancer: epidemiological data from Australia and New Zealand. In: Young AR, Bjorn LO, Moan J, Nultsch W, editors. Environmental UV photobiology. London: Plenum; 1993. p. 233-54
8. Kricker A, Armstrong BK, Jones ME, Burton RC. Health, solar UV radiation, and environmental change. Lyon, France: International Agency for Research on Cancer; 1993.
9. Elwood JM. Melanoma and sun exposure: contrasts between intermittent and chronic exposure. World J Surg 1992;16:157-65.
10. Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene 2003;22:3042-52.
11. Desmond RA, Scong S. Epidemiology of malignant melanoma. Surg Clin N Am 2003;83:1-19.
12. Ward EM, Burnett CA, Ruder A, et al. Industries and cancer. Cancer Causes Control 1997;8:356-70.
13. Sinks T, Steele G, Smith AB, et al. Mortality among workers exposed to polychlorinated biphenyls. Am J Epidemiol 1992;136:389-98.
14. Loomis D, Browning SR, Schenck AP, et al. Cancer mortality among electric utility workers exposed to polychlorinated biphenyls. Occup Environ Med 1997;54:720-8.
15. Robinson CF, Petersen M, Paul S. Mortality patterns among electrical workers employed in the US construction industry. Am J Ind Med 1999;36:630-7.
16. Nelemans PJ, Scholte R, Groendendal H, et al. Melanoma and occupation: results of case control study in the Netherlands. Br J Ind Med 1993;50:642-6.
17. Sarna T, Swartz HA. The physical properties of melanin. Review In: Nordlund J, Boiss RE, Hearing VJ, King RA, Ortonne J-P, editors. The pigmentary system. New York: Oxford University Press 1998. p. 333-58.
18. Sarna T, Duleba A, Korytowski W, Swartz H. Interactions of melanin with oxygen. Arch Biochem Biophys 1980;200:140-8.
19. Meyskens FL Jr, Van Chau H, Tohidian N, Buckmeier JA. Luminol-enhanced chemiluminescence response of human melanocytes and melanoma cells to hydrogen peroxide stress. Pigment Cell Res 1997;10:184-9.
20. Meyskens FL Jr, McNulty SE, Buckmeier JA, et al. Aberrant redox regulation in human metastatic melanoma cells compared to normal melanocytes. Free Radic Biol Med 2001;31:799-808.
21. Gidanian S, Farmer PJ. Redox behavior of melanins: direct electrochemistry of DHI-melanin and its Cu and Zn adducts. J Inorg Biochem 2002;89:54-60.
22. Szpaganicz B, Kong P, Farmer PJ. Metal binding by melanins: studies of colloidal DHI-melanin, and its complexation by Cu(II), and Zn(II) ions. J Inorg Biochem 2002;89:45-53.
23. Farmer PJ, Gidanian S, Shahandeh B, et al. Melanin as a for melanoma chemotherapy: pro-oxidant effect of oxygen and metals on melanoma viability. Pigment Cell Res 2003;16:273-9.
24. Larson BS. The toxicology and pharmacology of melanin. In: Nordlund JJ, Boiss y RE, Hearing VJ, King RA, Ortonne J-P, editors. The pigmentary system. New York:Oxford University Press; 1998. p. 373-390.
25. Picardo M, Maresca V, Eibenschutz L, et al. Correlation between antioxidants and phototypes in melanocytes cultures. A possible link of physiologic and pathologic relevance. J Investig Dermatol 1999;113:424-5.
26. Picardo M, Grammatico P, Roccella F, et al. Imbalance in the antioxidant pool in melanoma cells and normal melanocytes from patients with melanoma. J Investig Dermatol 1996;107:322-6.
27. Dellavalle RP, Nicholas MK, Schilling L. Melanoma chemoprevention: a role for statins or fibrates. Am J Ther 2003;10:203-10.
28. Buchwald H. Cholesterol inhibition, cancer and chemotherapy. Lancet 1999;339:1154-6.
29. Jimbow, Kowichi. Current update and trends I melanin pigmentation and melanin biology. Keio J Med 1995;44:9-18.
30. Rhodes AR, Seki Y, Fitzpatrick TB, Stern RS. Melanosomal alterations in dysplastic melanocytic nevi. Cancer (Phila) 1988;61:358-69.
31. Menasche G, Feldmann J, Houdusse A, et al. Biochemical and functional characterization of Rab27a mutations occurring in Griscelli syndrome patients. Blood 2003;101:2736-42.
32. Starcevic M, Nazarian R, Dell'Angelica EC. The molecular machinery for the biogenesis of lysosome-related organelles: lessons from Hermansky-Pudlak syndrome. Semin Cell Dev Biol 2002;13:271-8.
33. Pavel S, Smit NP, van der Meulen H, et al. Homozygous germline mutation of CDKN2A/p16 and glucose-6-phosphate dehydrogenase deficiency in a multiple melanoma case. Melanoma Res 2003;13:171-8.
34. Le Marchand L. Dietary factors in the etiology of melanoma. Clin Dermatol 1999;10:79-82.
35. Meyskens FL, Farmer PJ, Fruehauf J. Redox regulation in human melanocytes and melanoma. J Pigment Cell Res 2001;14:148-54.
36. Miles AT, Hawksoworth GM, Beattie JH, Rodilla V. Induction, regulation, degradation, and biological significance of mammalian metallothioneins. Crit Rev Biochem Mol Biol 2000;35:35-70.
37. Simpkins CO. Metallothionein in human disease. Cell Mol Biol 2000;46:465-88.
38. Nordberg M, Nordberg GF. Toxicological aspects of metallothionein. Cell Mol Biol 2000;46:451-63.
39. Sugita K, Yamamoto O, Asahi M. Immunohistochemical analysis of metallothionein expression in malignant melanoma in Japanese patients. Am J Dermatopathol 2001;23:29-35.
40. Smith DR, McNeill F. In vivo measurement and speciation of nephrotoxic metals. Toxicol Metals 1996;737-50.
41. Dillon CT, Kennedy BJ, Lay PA, et al. Implementation of X-ray microscopy and micro-XANES analysis for investigations of the cellular uptake and cellular metabolism of transition metals. J Physique IV: Proc 2003;293-6.
42. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAFF mutations in nevi. Nat Genet 2003;33:19-20.
43. Walker GJ, Hayward NK. Pathways to melanoma development: lessons from the mouse. J Investig Dermatol 2002;119:783-92.
44. Demierre MF, Nathanson L. Chemoprevention of melanoma: an unexplored strategy. J Clin Oncol 2003;21:158-65.